Friday, Nov 22, 2019

Speakers/moderators for each session have been advised to incorporate 25% of interactivity with the audience directly into their presentation or 25% of interactivity to be included at the end of the session in the form of a panel discussion with the audience.

0730	Registration and breakfast
0815	Opening remarks Taymaa May, MD and Stephanie Lheureux, MD
Session I: Surgical approach in cervical cancer Moderator: Lilian Gien, MD
0830	Minimally invasive versus open surgery in cervical cancer- results of the LACC trial Pedro Ramirez, MD
0915	Cervical cancer outcomes in Ontario Sarah Ferguson, MD
0945	Is there still a role for minimally invasive surgery in cervical cancer? Al Covens, MD
1015	Panel discussion and Q&A with audience
1045	Health break
Session II: Adjuvant therapies and their unintended effects Moderator: Eric Leung, MD
1100	Managing side effects of emerging targeted therapies.  Josée-Lyne Ethier, MD
1125	Challenges when caring for patients on PARP inhibitors Valerie Bowering, RN
1145	IMBRASE- Immune and Molecular Therapy Bolstering and Supporting Patient Adverse Events Program Nancy Gregorio, RN
1105	Managing late side effects of radiotherapy Jenn Croke, MD
1230	Lunch
Session III: PARP inhibitors in ovarian cancer Moderator: Barry Rosen, MD
1330	The role of PARP inhibitors in newly diagnosed ovarian cancer- Results of the SOLO 1 trial Amit Oza, MD
1415	Somatic testing in ovarian cancer Tracy Stockley, PhD
1445	Health break
Session IV: Options for women with BRCA mutation Moderator: Joan Murphy, MD
1500	BRCA testing in Ontario Jeanna McCuaig, (C)CGC
1530	Tumor Board discussion- Bevacizumab versus PARP inhibitor for patients with stage IV ovarian cancer who have a BRCA mutation Panel: Hal Hirte, MD; Allison Ball, MD, Marcus Bernardini, MD
1615	Closing Remarks Taymaa May, MD and Stephanie Lheureux, MD
1630	End of day